Drug Development

BioVex announces beginning of patient dosing in phase II trials of OncoVEXGMCSF for cancer

Published in Biotech Business Week, March 13th, 2006

BioVex, Inc., announced that the first patients in its phase II clinical trials of OncoVEXGMCSF in malignant melanoma and in head and neck cancer had received their initial doses of the therapeutic treatment.

The melanoma trial is a 50 patient multicenter study. The first dosing took place at the Mary Crowley Medical Research Center, Dallas, Texas. The principal investigator is John Nemuniatis. The primary endpoint of the study is tumor response rate with secondary endpoints including time to disease progression and median survival time.

The head and neck cancer trial is a 16 patient open label study in combination with chemoradiotherapy. It is being...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2006-03-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry